![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, October 20, 2021 7:44:36 AM
https://seekingalpha.com/article/4459748-inmune-bio-a-no-brainer-investment?v=1634579553#comment-90395121
Someone asked the author how he compares it with AVXL and his answer was:
Carl Kestens
New:
Today, 6:56 AM
Premium
Marketplace
Comments (64)
|
| @jhawker8 Anavex has almost no understanding of the MoA and all of the (side) effects of their drug, and at least investors need to rely on the few things out there. Yes, there has been a publication recently in a medical journal elucidating this MoA (www.biospace.com/...), but in no way does this compare to (i) the more than hundred articles elucidating the probably most crucial role of soluble TNF in neuroinflammation in neurodegenerative diseases and TRD/bipolar disorder that I have found over the past months many of which are published on INMB's website (www.inmunebio.com/...), (ii) the role of neuroinflammation and aging in diseases of the CNS, and (iii) the testing of XPro in animals in different diseases and possible side effects (there are none so far). The approach of INMB then differs to that of AVXL in that INMB bases itself on research that has been abundantly performed and written about in the last ten years, mostly on the causes of neurodegeneration.
INMB also seems to be taking a different approach with regards to their study design; step by step, massive neuroinflammation data first, then neurodegeneration results, then cognition. But the focus is there, and they are moving fast forward at this time. I don't see that focus in AVXL; AVXL investors have been without news on the AD drug development so much, that one comes to think AVXL has dropped that idea altogether. It may not be so, but then why are they waiting?
Furthermore, I see INMB clearly steering away from the old view on Alzheimer's, more than AVXL is doing.
Also, INMB communicates with its investors really well through extremely informative long webinars.
And this, all the while with the focus on proceeding forward with many drugs at the same time, and communicating about all of those a lot, if one cares to take the time to study them.
Lastly, when I read about AVXL's approach, and their SIGMAR1 receptor involvement, I always fear that their results won't last, as receptors may be worn out. INMB's data stretches over 6 months, and data improves. That means that risk is off the table, as it is in Cassava Sciences. That is a step forward beyond belief (that the market is currently forgetting in Cassava Sciences, but that's another story and wasn't your question).
Finally, I like INMB's idea of limiting their potential clientele to AD patients who have neuroinflammation; that shows full understanding of their potential and their limits at the same time; they basically differentiate within AD, where others dont'.
For the record, I am not saying I don't give AVXL's approach a chance, look at their Parkinson's data. But in light of the above, I know what my preference is. Plus, AVXL's market cap is 1.36 billion and INMB's is 300 million, with much more drug potential in the pipeline for INMB. That's another major difference; the company's diversification further derisks it compared to other biotech companies.
That's about 7 differences in approach I am seeing. Perhaps not all may hold true; it's been about 7 months since I have reviewed AVXL.
I intend to make a detailed comparison of INMB, CRTX, ANVS, AVXL, SAVA and possible other companies focused on neurodegenerative diseases over the coming months in a larger document, that I plan to finalize by January / February 2022, but currently still lack the time to do so. I will be happy to communicate it to you at that time.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/12/2024 09:45:00 AM
- Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/11/2024 11:30:00 AM
- Class Action Filed Against Anavex Life Sciences Corporation (AVXL) - May 13, 2024 Deadline to Join - Contact The Gross Law Firm • PR Newswire (US) • 04/09/2024 09:45:00 AM
- Anavex Life Sciences Corporation Class Action: The Gross Law Firm Reminds Anavex Life Sciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 13, 2024 - AVXL • PR Newswire (US) • 04/05/2024 09:45:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 04/02/2024 09:45:00 AM
- Lost Money on Anavex Life Sciences Corporation(AVXL)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 03/29/2024 09:45:00 AM
- Investors who lost money on Anavex Life Sciences Corporation(AVXL) should contact The Gross Law Firm about pending Class Action - AVXL • PR Newswire (US) • 03/26/2024 09:45:00 AM
- Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 03/25/2024 11:30:00 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM